Pharmaceutical patent examination outcomes in the Dominican Republic
Tóm tắt
In the Dominican Republic, the legal provisions requiring the substantive examination of patent applications were enacted 20 years ago, along with the implementation of the TRIPS agreement. Prior to this, the country had a registration system in which all applications that were filed ended up being registered. This offers an opportunity to explore the outcomes of applications in a country that embarked on substantive patent examinations relatively recently. and which has drawn comparatively less attention in academic research related to the rigorousness of patentability criteria. Based on a novel dataset of pharmaceutical patent applications filed in the Dominican Republic between 2000 and 2015, I find that only 16% of them were granted. This seems surprisingly low. However, I also find that grant rates may be influenced by several factors, including some that are not strictly related to patent examination. In particular, some applications may have been disposed of without a grant because their applicants acquired additional knowledge, indicating that the underlying inventions lacked commercial value. This calls for more attention towards other policies – such as legal provisions and institutional arrangements designed to accelerate the speed of patent examination – which could also be determinants of grant rates.
Từ khóa
Tài liệu tham khảo
Abud, M. J., Hall, B., & Helmers, C. 2015. An empirical analysis of primary and secondary pharmaceutical patents in Chile. PLoS ONE, 10: e0124257. https://doi.org/10.1371/journal.pone.0124257.
Ali, F., Rajagopal, S., Raman, V., & John, R. 2018. Pharmaceutical patent grants in India: How our safeguards against evergreening have failed, and why the system must be reformed. AccessIBSA White Paper.
Burdon, M., & Sloper, K. 2003. The art of using secondary patents to improve protection. Journal of Medical Marketing, 3(3): 226–238. https://doi.org/10.1057/palgrave.jmm.5040125.
Correa, C. M., Balleri, C., Giulietti, M., Lavopa, F., Musetti, C., Palopoli, G., Pippo, T., De la Puente, C., & Lowenstein, V. 2011. Patentes, suministro de medicamentos y protección de la Salud Pública; Patents, supply of medicines and protection of public health. Rev. argent. salud pública, 2: 19–27.
Correa, C. 2007. Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health Perspective, WHO-ICTSD-UNCTAD.
Drahos, P. 2010. The global governance of knowledge: Patent offices and their clients. Cambridge: Cambridge University Press.
Drahos, P. 2007. “Trust me”: Patent offices in developing countries. Canberra: Centre for Governance of Knowledge and Development.
Ellery, T., & Hansen, N. 2012. Pharmaceutical lifecycle management: Making the most of each and every brand. Hoboken: Wiley.
Gil Abinader, L. 2015a. Desempeño institucional de la oficina dominicana de patentes. Buenos Aires: FLACSO Argentina.
Gil Abinader, L. 2015b. Encouraging the use of patent information… Through research competition? Intellectual Property Watch.
Graham, S. J. H., Marco, A. C., & Miller, R. The USPTO patent examination research dataset: A window on the process of patent examination (November 30, 2015).
Guzmán, M. A. 2018. La industria farmacéutica crece entre 13 y 14% anual. Periódico Hoy.
Howard, L. 2007. Use of patents in drug lifecycle management. Journal of Generic Medicines, 4: 230–236. https://doi.org/10.1057/palgrave.jgm.4950065.
Kapczynski, A., Park, C., & Sampat, B. 2012. Polymorphs and prodrugs and salts (Oh My!): An empirical analysis of “secondary” pharmaceutical patents. PLoS ONE, 7: e49470.
Kesselheim, A. 2007. Intellectual property policy in the pharmaceutical sciences: The effect of inappropriate patents and market exclusivity extensions on the health care system. The AAPS Journal, 9(3): E306–E311.
IMPI. 2010. Search and substantive examination support for patent applications in Central America and Dominican Republic (CADOPAT) and other economies. 2010/IPEG31/009. México, D.F.: IMPI
Lanjouw, J., Pakes, A., & Putnam, J. 1998. How to count patents and value intellectual property: The uses of patent renewal and application data. Journal of Industrial Economics, 46(4): 405–432
Lazaridis, G., & van Pottelsberghe de la Potterie, B. 2007. The rigour of EPO’s patentability criteria: An insight into the “induced withdrawals”, No 07-007.RS, Working Papers CEB, ULB – Universite Libre de Bruxelles
Marco, A., Tesfayesus, A., & Toole, A. 2017. Patent Litigation Data from US District Court Electronic Records (1963–2015). USPTO Economic Working Paper No. 2017-06.
Martinez, C. 2010. Insight into different types of patent. Families, OECD Science, Technology and Industry. Working Papers, 2010/02, OECD Publishing.
ONAPI. 2013. Estrategia nacional de propiedad intelectual de la República Dominicana 2012. Una herramienta para promover la innovación y la competitividad mediante la utilización estratégica de la propiedad intelectual. Santo Domingo: ONAPI
PhRMA. 2000. Pre-hearing statement and request to appear at the GSP public hearing for the Dominican Republic, 65 Fed. Reg. 11104 (March 1, 2000).
Sampat, B. N., & Shadlen, K. C. 2015. TRIPS implementation and secondary pharmaceutical patenting in Brazil and India. Studies in Comparative International Development, 50(2): 228–257
Sampat, B. N., & Shadlen, K. C. 2017. Secondary pharmaceutical patenting: A global perspective. Research Policy, 46(3): 693–707
Sampat, B. N., & Shadlen, K. C. 2018. Indian pharmaceutical patent prosecution: the changing role of Section 3(d). PLOS ONE. https://doi.org/10.1371/journal.pone.0194714
Schwartz, D., Sichelman, T., & Miller, R. 2019. USPTO Patent Number and Case Code File Dataset Documentation. USPTO Economic Working Paper No. 2019-05.
Secretaría de Estado de Educación Superior, Ciencia y Tecnología. 2008. Plan Estratégico de Ciencia, Tecnología e Innovación 2008-2018.
Shadlen, K. 2017. Coalitions and compliance: The political economy of pharmaceutical patents in Latin America. Oxford: Oxford University Press.
Shadlen, K. 2012. The rise and fall of ‘prior consent’ in Brazil. WIPO Journal, 3(1): 103–12
U.S. Embassy in Santo Domingo. 1997. Update on pharmaceutical patent issues. State reference 133570.
U.S. Embassy in Santo Domingo. 1999. Implementing TRIPS obligations in the Dominican Republic. State reference 164771.
U.S. Embassy in Santo Domingo. 2000. Ambassadors’ criques of patent legislation welcomed by Dominican congressional leader, but prospects for an improved bill remain uncertain. State reference 51065.
UNCTAD. 2012. Examen de las políticas de ciencia, tecnología e innovación: República Dominicana. UNCTAD/STICT/2012/1. Geneva: UNCTAD
USPTO. 1997. Comments on draft patent law. Document number 1997State133570.
USTR. GSP 1999 annual review. IPR country practice cases. Public hearing.
Yamauchi, I., & Nagaoka, S. 2015. An economic analysis of deferred examination system: Evidence from a policy reform in Japan. International Journal of Industrial Organization, 39: 19–28.